On July 15, the third Signal Series event of the new ISPOR virtual series Signal, “National Institute for Health and Care Excellence (NICE), UK: Transformation in Action” took place.
NICE is transforming what it does to be more responsive and dynamic, using a range of sources of data and evidence, while retaining its independent and robust methods.
In the July episode of the ISPOR Signal series we heard how NICE intends to be at the forefront of anticipating and rapidly evaluating new and existing technologies to provide independent, world- leading assessments of value for the UK’s National Health Service and improved access for patients.
We learned about how NICE’s new and ambitious 5- year strategy will build on its trusted reputation for rigor and independence, while at the same time keeping ahead of the challenges of a rapidly changing world.
We discovered how NICE plans to speed up the existing evaluation pathway for new medicines by proactively identifying innovative and cost- effective health technologies, and by working closely with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and other partners in the UK healthcare ecosystem to ensure rapid UK access to pioneering new treatments post EU- exit, via the Innovative Licensing and Access Pathway.
The session also looked at how NICE plans to:
- Develop leading capabilities and standards for routinely using real- world data to inform all aspects of its work.
- Drive the future research agenda and funding priorities through new collaborations with academia, government, and industry.
- Remain at the forefront of anticipating and rapidly evaluating digital health technologies